Scientists have uncovered a key mechanism behind a rare form of hereditary deafness, opening a potential path for gene therapy that could one day restore hearing in children born with Usher syndrome. The discovery comes at a pivotal moment, just months after the U.S. Food and Drug Administration approved the first-ever gene therapy for inherited deafness, a milestone that has energized the field.
Published in Nature Communications, the study led by researchers at the University of Florida, the University of Virginia, and the University of Colorado reveals how mutations in the MYO7A gene disrupt a critical tuning system in the ear’s sound-sensitive hair cells. Using genetic sequencing of hair cells in the cochlea, the team identified a previously unknown form of the protein, which they named MYO7A-N. This variant acts like a nanomotor, constantly adjusting tension on microscopic filaments that bridge hair cell “antennas.” When these filaments are not properly tensioned, they cannot detect sound accurately, similar to a violin string that is too loose or too tight.
The researchers found that different forms of MYO7A change in abundance as hair cells switch between detecting high and low pitch sounds. “Our paper is the first to show that an array of differing MYO7A proteins contributes to tuning this ‘violin string,’” said Jonathan Bird, a neuroscientist at UF’s McKnight Brain Institute. “When we then isolated and purified these MYO7A proteins, we found they had different motor activities. As you increase the amount of MYO7A-N, you can change the mechanical tuning of the system.” The finding reveals an unexpected layer of molecular diversity within the ear’s delicate machinery, the authors reported.
What This Means for Usher Syndrome Patients
Usher syndrome type 1B is a rare and devastating condition that causes both deafness and blindness from birth. While the recent FDA-approved gene therapy targets a different genetic form of deafness involving the otoferlin gene, this new study lays the groundwork for a similar approach for MYO7A-related hearing loss. The research suggests that any future gene therapy for Usher syndrome must restore all multiple forms of the MYO7A protein to maximize the chance of success.
Looking ahead, the study provides a new framework for developing treatments that could one day tune the ear’s hair cells back to working order. While human trials remain years away, the discovery marks a critical step forward in understanding how to repair the ear’s natural sound detection system. For families affected by Usher syndrome, this mechanistic insight offers a clear and hopeful direction for research that could eventually change the lives of children born unable to hear or see.